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CASE REPORT
Hemophagocytic syndrome (HPS) is a clinico-
pathologic entity characterized by high-grade fever,
hepatosplenomegaly, pancytopenia, hyperferri-
tinemia, and hypertriglyceridemia.1 HPS may be
primary, as observed in familial hemophagocytic
lymphohistiocytosis, X-linked lymphoprolifera-
tive syndrome, and Chediak-Higashi syndrome.2
It may be secondary to malignancies, infections,
autoimmune diseases, or drugs.3 Clinical histo-
logic findings include accumulation in the retic-
uloendothelial system of activated macrophages
showing phagocytosis of hematopoietic cells.
HPS occurs in children as a familial disease, in
adults in association with malignant neoplasm,
and in both as a secondary event in the course 
of acute infection, generally of viral etiology or
triggered by causes not always identified.4 We re-
port the case of a 28-year-old woman who pre-
sented with HPS and cellulitis-like skin lesions
over her lower legs. She was treated with etoposide
for the fulminant HPS. Four months later, several
subcutaneous nodules developed. Biopsy showed
subcutaneous panniculitis-like T-cell lymphoma.
This case is a rare example of occult lymphoma
presenting with fulminant HPS and cellulitis-like
skin lesions.
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Hemophagocytic syndrome (HPS) may be primary or secondary to malignancies, infections, autoimmune
diseases, or drugs. In most cases, HPS occurs at the same time as the diagnosis of underlying malignancy or
when it relapses. In rare situations, the neoplastic disease can be occult, even for more than a decade. We
report the case of a 28-year-old woman admitted because of HPS. Treatment with etoposide for fulminant
HPS was effective. Four months later, she was admitted again because of newly developed subcutaneous
nodules and cellulitis-like skin lesions over her legs. Excisional biopsy of subcutaneous nodule showed
subcutaneous panniculitis-like T-cell lymphoma. After etoposide, solumedrol, cytosine arabinoside, and
cisplatin regimen chemotherapy, both skin lesions and subcutaneous nodules disappeared. In conclusion,
for patients presenting with HPS and cellulitis-like skin lesions, occult lymphoma should be considered,
which might not be diagnosed for months, even years. Adequate treatment, including steroid and chemo-
therapy against malignant lymphoma, should be started as soon as possible for patients with fulminant
HPS because of its fatal course. [J Formos Med Assoc 2007;106(2 Suppl):S55–S59]
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Case Report
A 28-year-old woman was admitted after having
the following syndromes for 2 days: fever up to
39°C, chills, general soreness, arthralgias, and
headache. Urine and blood cultures were sterile.
Cerebral spinal fluid study showed initial pres-
sure of 125 mmH2O with no white blood cells
(WBCs). Protein, glucose, and lactate dehydroge-
nase (LDH) in cerebral spinal fluid were 37 mg/dL
(normal, 15–45), 53 mg/dL (normal, 50–75), and
56 U/L (normal, < 20), respectively. Viral serology
tests, including human immunodeficiency virus,
Epstein–Barr virus, cytomegalovirus, and varicella
zoster virus, were all negative. Epstein–Barr virus
was also not detected by real-time quantitative
polymerase chain reaction. Renal and liver func-
tion tests were within normal limits, except for
elevated LDH (570 U/L; normal, 120–240). Her
serum triglyceride level was 110 mg/dL (normal,
20–200). Both prothrombin time and activated
partial thromboplastin time were not prolonged.
Sonography of the abdomen showed no special
infection source, except hepatosplenomegaly. No
active lesions were noted on chest X-ray. Antinu-
clear antibody and rheumatoid factor were nega-
tive. Fever persisted despite empirical antibiotics.
During admission, fever-related evanescent skin
rash appeared on her trunk. Her ferritin increased
from 1371 ng/mL to 118,850 ng/mL (normal,
9–20) in 2 weeks. Her leukocyte, hemoglobin, and
platelet levels dropped from 3 × 109/L to 1.57 ×
109/L (normal, 4 × 109 to 8 × 109), 12.4 g/dL to
8.0 g/dL (normal, 12–14), and 190 × 109/L to 41 ×
109/L (normal, 140 × 109 to 400 × 109), respec-
tively. Bone marrow examination showed a hypo-
cellular marrow with hemophagocytosis (Figure 1).
Skin biopsy of the evanescent rash showed peri-
vascular infiltration of small lymphoid cells in the
upper dermis. No evidence of vasculitis or leukemic
cells was found. Serum aspartate aminotransferase,
alanine aminotransferase, and LDH increased to
487 U/L, 319 U/L, and 1774 U/L, respectively. HPS
was diagnosed by fulfilling the criteria of hemo-
phagocytosis in bone marrow, fever up to 39°C,
pancytopenia, elevated LDH, hyperferritinemia,
and hepatosplenomegaly. Neither methylpredni-
solone pulse therapy (750 mg/day for 3 con-
secutive days) nor intravenous immunoglobulin
reduced the fever. Because of the fulminant HPS,
although the cause was unknown, she was treated
with etoposide. Fever and skin rash subsequently
subsided after the treatment. Her hemogram re-
turned to normal. Repeated bone marrow exami-
nations showed normal bone marrow. The patient
was discharged in a stable condition 1 month after
being admitted.
Four months later, she suffered from painful
erythematous macupapules with local heat over
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Figure 1. Bone marrow aspiration smear shows activated
macrophages with phagocytosis of hematopoietic cells, in-
cluding mature red blood cells, nucleated red blood cells,
and neutrophils (arrow) (hematoxylin & eosin, 400×).
Figure 2. Subcutaneous nodule biopsy. Histologic examina-
tion shows panniculitis-like T-cell lymphoma (hematoxylin &
eosin, 100×).
her lower legs. She also had intermittent fever.
Her hemogram was normal. Two days later, mul-
tiple 1×1cm subcutaneous nodules developed
over her upper back, posterior neck, and left arm.
The nodules were firm, well defined, and fixed. 
A left arm nodule was excised. Microscopic exam-
ination found subcutaneous panniculitis-like T-cell
lymphoma (Figure 2). Section disclosed a tumor
in a panniculitis pattern with perivascular infiltra-
tion from deep dermis to subcutaneous fat.
Immunohistochemical staining for CD3 and
CD8 was positive (Figure 3), but not for CD4
and CD45. In situ hybridization for Epstein–Barr
virus encoded ribonucleic acid showed negative
nuclear labeling of tumor cells. She was treated
with etoposide, solumedrol, cytosine arabinoside,
and cisplatin (ESHAP) chemotherapy regimen.
The lower leg skin lesions and subcutaneous nod-
ules diminished. She completed her five cycles of
ESHAP regimen chemotherapy in the following
6 months and remained in a stable condition for
another half year.
Discussion
HPS is a clinicopathologic entity characterized by
high-grade fever, hepatosplenomegaly, pancytope-
nia, hyperferritinemia, and hypertriglyceridemia.1
Uncontrolled T-lymphocyte activation might play
a critical role in promoting macrophage activa-
tion and the formation of a cytokine network.5
In patients with active HPS, serum levels of the 
T helper 1 lymphocyte cytokines interferon-γ, in-
terleukin 12, and interleukin 18 are significantly
higher than in the remission phase of the disease
or in healthy controls.6,7
HPS has since been associated with a variety
of viral, bacterial, fungal, and parasitic infections,
as well as with collagen-vascular diseases and ma-
lignancies, in particular lymphoma.8,9 Takahashi
et al3 conducted a clinical analysis of 52 adult
patients with HPS to find that underlying diseases
are heterogeneous. Lymphoma-associated HPS is
clearly the most common etiology of adult HPS,
regardless of the initial presentation.
Identification of the etiologies of HPS is usu-
ally time-consuming. Delayed treatment of HPS
would result in a fatal outcome due to its fulmi-
nant clinical course. According to guidelines pro-
posed by Takahashi et al,3 when HPS is refractory
to glucocorticoid or intravenous immunoglobulin
therapy for 2 weeks, chemotherapy against malig-
nant lymphoma is the recommended treatment.3
In most cases, diagnosis of HPS occurs at the
same time as diagnosis of the underlying malig-
nancy or with relapse of the malignancy.10 In rare
situations, however, the neoplastic disease can be
occult for months, and even for years.11,12 In our
patient, the subcutaneous panniculitis-like T-cell
HPS and occult T-cell lymphoma
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Figure 3. Immunohistochemical staining of subcutaneous nodule biopsy with (A) CD3 and (B) CD8 shows positively
stained atypical lymphocyte cells (400×).
lymphoma was occult for 4 months. On the
other hand, the initial presentation of subcuta-
neous panniculitis-like T-cell lymphoma with
HPS mimics several diseases, such as cellulitis,
adult onset Still’s disease, and sepsis. Moreover,
viral infection-related HPS cannot be entirely
ruled out by normal cultures and serology tests
before pathologic evidence of malignancy. During
the latent period, most skin biopsies fail when
the cellulitis-like lesions are present. Repeated
biopsies are usually required.11 Subcutaneous
nodule biopsy provides a reliable diagnosis.
Subcutaneous panniculitis-like T-cell lym-
phoma is a post-thymic T-cell neoplasm charac-
terized by lipotrophic lymphohistiocytic infiltrate
commonly presenting as subcutaneous nodules
resembling panniculitis. Two clinical courses are
reportedly observed:11 a prolonged course of re-
current panniculitis or a rapid clinical deteriora-
tion secondary to the HPS. Low peripheral WBC
count, elevated LDH, presence of HPS at diagno-
sis, and expression of the γ/δ T-cell receptor by
tumor cells are poor prognostic factors.11,13 The
mortality rate of subcutaneous panniculitis-like
T-cell lymphoma is around 50% with a mean
survival of 22 months.11 The frequency of HPS in
subcutaneous panniculitis-like T-cell lymphoma is
around 33%.13 When subcutaneous panniculitis-
like T-cell lymphoma is combined with HPS, the
mortality rate is even higher, about 81%.11
Even though immunosuppressive therapy and
radiotherapy are alternative treatments for sub-
cutaneous panniculitis-like T-cell lymphoma,13–15
anthracycline-based chemotherapy regimens pro-
vide both better efficacy and longer remission
duration.13 In the review by Weenig et al,11 one or
more complete remissions were reported in 32%
of cases, and 54% of the remissions lasted longer
than 6 months. For subcutaneous panniculitis-like
T-cell lymphoma associated HPS patients, how-
ever, conventional chemotherapy did not change
the outcome.11 Patients treated aggressively with
stem cell transplantation appeared to have an
improved overall survival.16
In summary, subcutaneous panniculitis-like
T-cell lymphoma is a rare disease accompanied
by HPS. At the beginning, the diagnosis might 
be confused with adult onset Still’s disease, over-
whelming infection, viral infection-related HPS, or
cellulitis. In rare situations, the underlying malig-
nancy might be occult for months to years. For
any suspected cases, early multiple agent chemo-
therapy is necessary to avoid fatal outcome from
the disease’s aggressive behavior.
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